Related Experiment Video
Updated: May 26, 2026
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
PET/CT in anal cancer - is it worth doing?
1Department of Radiology, Derriford Hospital, Plymouth, Devon, UK. tobywells@doctors.net.uk
Clinical Radiology
|January 3, 2012
Summary
2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)/computed tomography (CT) significantly impacts initial staging for anal cancer, altering management in many cases. Its role in post-treatment follow-up is less defined, suggesting selective use for complex cases.
Area of Science:
- Oncology
- Radiology
- Nuclear Medicine
Background:
- Anal cancer management relies on multidisciplinary input.
- Accurate staging is crucial for effective treatment planning.
- The role of advanced imaging like PET/CT in anal cancer needs evaluation.
Purpose of the Study:
- To assess the utility of 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)/computed tomography (CT) in anal cancer management.
- To determine its impact on initial staging and post-treatment follow-up.
Main Methods:
- Retrospective analysis of PET/CT scans in anal cancer patients.
- Comparison of PET/CT findings with conventional imaging (CT, MRI).
- Evaluation of changes in tumor staging and patient management.
Main Results:
- PET/CT altered the stage in 36% of anal cancer cases (17% increased, 19% decreased).
- Management decisions were affected by PET/CT findings in 29% of patients.
- Initial staging showed more frequent alterations compared to follow-up imaging.
Conclusions:
- FDG PET/CT is valuable for routine initial staging of anal cancer.
- Its role in routine follow-up is uncertain; selective use is recommended for problem-solving or salvage surgery planning.
- Multidisciplinary discussion remains key in interpreting PET/CT findings for anal cancer management.
